Please login to the form below

Not currently logged in
Email:
Password:

Rozlytrek

This page shows the latest Rozlytrek news and features for those working in and with pharma, biotech and healthcare.

Fool’s gold or pot of gold? The challenges of demonstrating the value of tumour agnostic therapies

Fool’s gold or pot of gold? The challenges of demonstrating the value of tumour agnostic therapies

As Vitrakvi and Rozlytrek lead with their TA indications, the challenges faced by these therapies are wholly different to Keytruda. ... Vitrakvi and Rozlytrek target NTRK gene mutations and fusions in patients with locally advanced or metastatic disease

Latest news

More from news
Approximately 2 fully matching, plus 7 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Oxford University Press

Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...

Latest intelligence

Sustainability
Environment: where does the pharmaceutical industry stand?
...
The communication challenge of helping he next generation to be healthier
As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
Are we losing sight of what the democratisation of healthcare really looks like?
We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...